EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.

Lalami, Yassine; Specenier, Pol M; Awada, Ahmad; Lacombe, Denis; Liberatoscioli, Cecilia; Fortpied, Catherine; El-Hariry, Iman; Bogaerts, Jan; Andry, Guy; Langendijk, Johannes A; Vermorken, Jan B

doi:doi/10.1016/j.radonc.2012.08.006

Recherche avancée | Historique de recherche Mon DI-fusion | À propos de DI-fusion | Contact |

Citer

EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.

par Lalami, Yassine

;Specenier, Pol M ;Awada, Ahmad

;Lacombe, Denis ;Liberatoscioli, Cecilia ;Fortpied, Catherine ;El-Hariry, Iman ;Bogaerts, Jan ;Andry, Guy

;Langendijk, Johannes A ;Vermorken, Jan B
Référence Radiotherapy and oncology, 105, 2, page (238-240)
Publication Publié, 2012-11

Article révisé par les pairs

Résumé :

In this phase I/II study, the addition of lapatinib (LAP) was investigated in combination with the sequential use of both approaches TPF induction chemotherapy (ICT) followed by chemoradiation (CRT) in locally advanced larynx or hypopharynx squamous cell carcinoma.

Documents en relation

DI-fusion

Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours
par Schöffski, Patrick , Machiels, Jean Pascal , Rottey, Sylvie , Sadrolhefazi, Behbood , Musa, Hanny , Marzin, Kristell , Awada, Ahmad
Publication 2023-09
ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy
par Soumoy, Laura , Genbauffe, Aline , Mouchart, Lena , Sperone, Alexandra , Trelcat, Anne , Mukeba-Harchies, Léa , Wells, Mathilde , Blankert, Bertrand , Najem, Ahmad , Ghanem, Ghanem Elias , Saussez, Sven , Journé, Fabrice
Publication 2024-12
La planification préalable des soins : enjeux et défis pour les soignants en oncologie
par Libert, Yves
Publication 2024-04-02
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
par Kristeleit, Rebecca , Leary, Alexandra , Delord, Jean Pierre , Moreno, Victor , Oaknin, Ana , Castellano, Daniel , Shappiro, Geoffrey G.I. , Fernández, Cristian , Kahatt, Carmen , Alfaro, Vicente , Siguero, Mariano , Rueda, Daniel , Zeaiter, Ali , Awada, Ahmad , Santaballa, Ana , Zaman, Khalil , Sehouli, Jalid , Subbiah, Vivek
Publication 2023-10
The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer
par Hosseinzadeh, Leila , Kikhtyak, Zoya , Laven-Law, Geraldine , Pederson, Stephen , Puiu, Caroline , D’Santos, Clive S. , Lim, Elgene , Carroll, Jason S. , Tilley, Wayne D. , Dwyer, Amy , Hickey, Theresa
Publication 2024-02-05

Référencement	Visibilité	Pérennité	Facilité
Les publications encodées constituent la bibliographie académique de l'Université.	Les documents déposés sont indexés par les moteurs de recherche (Google Scholar,…).	Les documents déposés en open-access sont archivés au sein du réseau de préservation SAFE-PLN (www.safepln.org).	Les listes de publications sont compatibles avec le CV-ULB, le FNRS et accessibles sur le web.